Estimated read time 5 min read
Finance

AdAlta’s latest results bolster safety profile and dose selection for primary asset, enhancing partnering, reducing Phase 2 trial risks

0 comments

AdAlta’s AD-214 Phase 1 extension study interim data reinforce safety profile and dose selection Company preparing for partnering and Phase 2 trial of AD-214 into [more…]